Dasatinib Versus Nilotinib as Upfront Therapy for Treatment Naïve Chronic Myeloid Leukemia Chronic Phase

Trial Profile

Dasatinib Versus Nilotinib as Upfront Therapy for Treatment Naïve Chronic Myeloid Leukemia Chronic Phase

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Nilotinib (Primary) ; Dasatinib
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms DANIN
  • Most Recent Events

    • 12 Sep 2017 Planned End Date changed from 1 Jun 2022 to 1 Aug 2022.
    • 12 Sep 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Aug 2018.
    • 12 Sep 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top